SNY Earnings

SNY reported its FY2025Q4 earnings on 2026-01-29, showcasing a revenue of 13.00B against an estimate of 13.00B, resulting in a -1.36% surprise. The EPS was 0.89, surpassing the expected 0.84 by 5.95% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following SNY's FY2025Q4 earnings announcement on 2026-01-29, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, SNY's stock price tends to shift by an average of +1.58% in the 10 days leading up to earnings and -0.58% in the 10 days following, providing insight into potential market.

For , analysts estimate SNY’s annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.96% and EPS estimates Revise Upward by 0.75% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between SNY's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.96%, while EPS estimates moved Revise Upward by 0.75% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SNY's stock price typically moves by +1.58% in the 10 days before its earnings and -0.58% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

Sanofi's earnings call reflects strong financial performance, particularly with 9.7% sales growth and successful new product launches like Dupixent and Beyfortus. The company maintains a stable tax rate and is executing a significant share buyback program. While there are concerns about R&D expenses and margin growth, the optimistic guidance for Dupixent and new pipeline developments in immunology are positive indicators. The Q&A section reveals confidence in new acquisitions and market strategies, despite some uncertainties in regulatory outcomes and pricing pressures. Overall, the sentiment leans positive with potential stock price growth.